NCI OA SPECIAL NOTICE OF SUBCONTRACT OPPORTUNITY AT THE FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH

This Special Notice is not a formal Invitation for Bid (IFB), Request for Proposal (RFP), Request for Quotation (RFQ) nor any type of Solicitation for offers. In accordance with FAR 15.201(d), this Special Notice is intended FOR INFORMATIONAL PURPOSES ONLY in order to publicize the requirements of the Frederick National Laboratory for Cancer Research (FNLCR).

The FNLCR is a Government-Owned Contractor-Operated Federally Funded Research and Development Center (FFRDC) located at Fort Detrick, Maryland. The FNLCR partners with university, Government, and corporate scientists to speed the translation of laboratory research into new diagnostic tests and treatments for cancer and AIDS. FNLCR is a multi-program laboratory currently operated by Leidos Biomedical Research, Inc. (Leidos Biomed) for the National Cancer Institute (NCI) under Prime Contract No. 75N91019D00024 & HHSN261201500003I, which provides Operations and Technical Support (OTS) for the FNLCR.

The Government assumes no liability for reimbursement for any effort or associated costs to respond, nor for any information provided as a result of this Special Notice as no information is being requested. Please be advised that any submissions provided, despite that no information is requested, become Government property and will not be returned, nor will there be any ensuing discussions or debriefings.

Responses submitted to this Special Notice are not offers and cannot be accepted by the U.S. Government to form a binding contract. It is the responsibility of the interested parties to monitor this site and any sites referenced herein for additional information pertaining to business opportunities with the FNLCR, if any.

The NIAID, Division of Microbiology and Infectious Diseases (DMID), rapidly deploys resources to facilitate the conduct of time sensitive, high priority, global, collaborative clinical research critical to the mission of the NIAID and advancement of the National Institutes of Health (NIH) and Department of Health & Human Services (DHHS) Global Health Agendas. Fulfillment of this mission requires DMID to have the capacity to expeditiously support collaborative clinical research and conduct clinical trials both domestically and internationally.

First generation COVID-19 vaccines have dramatically decreased hospitalization and deaths, but efficacy against infection and symptomatic disease is significantly lower. There is also significant concern that if a new, more pathogenic variant arises, it may not be possible to ‘strain change’ the composition of the vaccine fast enough. Therefore, vaccines with better breadth of protection, durability, and efficacy against transmission, are needed to address these gaps.                      

Awardee shall provide laboratory assays and services to assess cytokines in nasal mucosa samples in up to nine (9) phase 1 trials and two (2) phase 2 trials within the NextGen program.

Leidos Biomedical Research, Inc. Point of Contact for a copy of Solicitation/RFP No: S26-111:

Tara Phillips, Sr. Subcontracts Administrator: tara.phillips@nih.gov   

For information concerning other opportunities with the FNLCR, please refer to:

https://frederick.cancer.gov/workwithus/solicitations